Published in Gene Therapy Weekly, September 11th, 2003
Neurologix's scientific founders recently became the first and only team to receive approval from the U.S. Food and Drug Administration (FDA) to conduct phase I human clinical trials of gene therapy for the treatment of Parkinson disease.
Patients are currently being recruited for the trial. Neurologix owns or licenses 14 patents and patent applications in this field,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.